Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Douglas Weaver

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
JAMA|July 7, 2011
Appropriateness of percutaneous coronary interventionPaul S Chan, Manesh R Patel, Lloyd W Klein, et al.
Circulation. Cardiovascular Quality and Outcomes|November 18, 2014
Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data RegistryRobert W Yeh, Matthew J Czarny, Sharon-Lise T Normand, et al.
European Heart Journal|November 21, 2015
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary interventionC Michael Gibson, Robert P Giugliano, Robert A Kloner, et al.
American Heart Journal|December 22, 2005
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registryTeresa L Kauf, Eric J Velazquez, David R Crosslin, et al.
Circulation|November 10, 2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysisPhilippe Gabriel Steg, Stefan James, Robert A Harrington, et al.
The American Journal of Cardiology|February 19, 2004
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)David E Kandzari, Christopher B Granger, Maarten L Simoons, et al.
American Heart Journal|February 28, 2016
Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomesJohn P Vavalle, Sean van Diepen, Robert M Clare, et al.
American Heart Journal|July 11, 2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothRajesh Janardhanan, Satish Kenchaiah, Eric J Velazquez, et al.
Clinical Chemistry|December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Journal of the American College of Cardiology|April 4, 2006
ST-segment elevation myocardial infarction: recommendations on triage of patients to heart attack centers: is it time for a national policy for the treatment of ST-segment elevation myocardial infarction?Timothy D Henry, James M Atkins, Michael S Cunningham, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
JAMA|July 7, 2011
Appropriateness of percutaneous coronary interventionPaul S Chan, Manesh R Patel, Lloyd W Klein, et al.
Circulation. Cardiovascular Quality and Outcomes|November 18, 2014
Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data RegistryRobert W Yeh, Matthew J Czarny, Sharon-Lise T Normand, et al.
European Heart Journal|November 21, 2015
EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary interventionC Michael Gibson, Robert P Giugliano, Robert A Kloner, et al.
American Heart Journal|December 22, 2005
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registryTeresa L Kauf, Eric J Velazquez, David R Crosslin, et al.
Circulation|November 10, 2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysisPhilippe Gabriel Steg, Stefan James, Robert A Harrington, et al.
The American Journal of Cardiology|February 19, 2004
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial)David E Kandzari, Christopher B Granger, Maarten L Simoons, et al.
American Heart Journal|February 28, 2016
Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomesJohn P Vavalle, Sean van Diepen, Robert M Clare, et al.
American Heart Journal|July 11, 2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothRajesh Janardhanan, Satish Kenchaiah, Eric J Velazquez, et al.
Clinical Chemistry|December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary SyndromeDaniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Journal of the American College of Cardiology|April 4, 2006
ST-segment elevation myocardial infarction: recommendations on triage of patients to heart attack centers: is it time for a national policy for the treatment of ST-segment elevation myocardial infarction?Timothy D Henry, James M Atkins, Michael S Cunningham, et al.
Pageof 9